JP2005532045A5 - - Google Patents

Download PDF

Info

Publication number
JP2005532045A5
JP2005532045A5 JP2004501558A JP2004501558A JP2005532045A5 JP 2005532045 A5 JP2005532045 A5 JP 2005532045A5 JP 2004501558 A JP2004501558 A JP 2004501558A JP 2004501558 A JP2004501558 A JP 2004501558A JP 2005532045 A5 JP2005532045 A5 JP 2005532045A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
alone
factor
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004501558A
Other languages
English (en)
Japanese (ja)
Other versions
JP4460443B2 (ja
JP2005532045A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/013521 external-priority patent/WO2003093422A2/en
Publication of JP2005532045A publication Critical patent/JP2005532045A/ja
Publication of JP2005532045A5 publication Critical patent/JP2005532045A5/ja
Application granted granted Critical
Publication of JP4460443B2 publication Critical patent/JP4460443B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004501558A 2002-05-01 2003-04-30 抗凝固剤としての新規組織因子標的化された抗体 Expired - Fee Related JP4460443B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37656602P 2002-05-01 2002-05-01
PCT/US2003/013521 WO2003093422A2 (en) 2002-05-01 2003-04-30 Novel tissue factor targeted antibodies as anticoagulants

Publications (3)

Publication Number Publication Date
JP2005532045A JP2005532045A (ja) 2005-10-27
JP2005532045A5 true JP2005532045A5 (https=) 2006-06-22
JP4460443B2 JP4460443B2 (ja) 2010-05-12

Family

ID=29401364

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004501558A Expired - Fee Related JP4460443B2 (ja) 2002-05-01 2003-04-30 抗凝固剤としての新規組織因子標的化された抗体
JP2004500787A Expired - Fee Related JP4567437B2 (ja) 2002-05-01 2003-04-30 抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004500787A Expired - Fee Related JP4567437B2 (ja) 2002-05-01 2003-04-30 抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質

Country Status (29)

Country Link
US (3) US7250168B2 (https=)
EP (2) EP1503785B1 (https=)
JP (2) JP4460443B2 (https=)
KR (2) KR101013697B1 (https=)
CN (2) CN100563709C (https=)
AR (1) AR039515A1 (https=)
AT (2) ATE427121T1 (https=)
AU (2) AU2003225255B2 (https=)
BR (2) BR0304659A (https=)
CA (2) CA2483910A1 (https=)
CR (1) CR7584A (https=)
DE (2) DE60326970D1 (https=)
DK (2) DK1503785T3 (https=)
EC (2) ECSP045468A (https=)
ES (2) ES2354419T3 (https=)
HK (1) HK1080372A1 (https=)
IL (3) IL164733A0 (https=)
MX (2) MXPA04010795A (https=)
NO (2) NO20035848L (https=)
NZ (2) NZ536243A (https=)
PE (1) PE20040597A1 (https=)
PL (2) PL210582B1 (https=)
PT (2) PT1503785E (https=)
RS (2) RS104504A (https=)
RU (2) RU2345789C2 (https=)
TW (1) TWI343388B (https=)
UA (2) UA85996C2 (https=)
WO (2) WO2003092602A2 (https=)
ZA (2) ZA200409692B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
AU7445900A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
US7312325B2 (en) 2000-09-26 2007-12-25 Duke University RNA aptamers and methods for identifying the same
HK1080372A1 (zh) * 2002-05-01 2006-04-28 Schering Aktiengesellschaft 作为抗凝剂的新型组织因子目标抗体
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7833978B2 (en) * 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
EP2460811A1 (en) 2004-04-22 2012-06-06 Regado Biosciences, Inc. Improved modulators of coagulation factors
CA2609262A1 (en) 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Anti-cd14 antibody fusion protein
US20090130104A1 (en) * 2005-10-05 2009-05-21 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
ES2353084T3 (es) * 2006-04-07 2011-02-25 Novo Nordisk Health Care Ag Complejo covalente de factor vii y factor tisular.
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
RU2433829C2 (ru) * 2006-10-06 2011-11-20 Асахи Касеи Фарма Корпорейшн Средство для лечения и/или улучшения состояния при диссеминированном внутрисосудистом свертывании
WO2008121814A1 (en) * 2007-03-28 2008-10-09 Ats Medical, Inc. Method for inhibiting platelet interaction with biomaterial surfaces
CN101855243A (zh) * 2007-09-20 2010-10-06 伯拉考成像股份公司 用于制备新的寡克隆抗体的方法
CA2708065C (en) * 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
WO2009086552A1 (en) * 2008-01-02 2009-07-09 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
SG2013061528A (en) * 2008-08-14 2015-03-30 Merck Sharp & Dohme Methods for purifying antibodies using protein a affinity chromatography
WO2010045518A1 (en) * 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2230251A1 (en) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antibodies specifically active in the coronary plaque and method for their identification
EP2470201A4 (en) * 2009-08-28 2013-01-30 Bayer Healthcare Llc COFACTORS ENABLING THE THROMBINIC ACTIVATION OF FACTOR VII AND THEIR USES
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
CN107188970A (zh) 2010-06-04 2017-09-22 株式会社蒂奥姆生物 具有因子vii活性的融合蛋白质
BR112012031727B1 (pt) 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
CL2011001887A1 (es) * 2010-08-05 2012-02-03 Council Scient Ind Res Construcciones de proteinas quimericas que poseen propiedades anticoagulantes y tromboliticas; secuencia de acido nucleico que las codifica; vector; celula huesped; metodo de preparacion; formulacion farmaceutica que las comprende; y su uso para inhibir la trombina.
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
US10954502B2 (en) * 2015-04-28 2021-03-23 Saint Louis University Thrombin-thrombomodulin fusion proteins as protein C activators
US11085031B2 (en) 2016-04-28 2021-08-10 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
US11104718B2 (en) * 2016-11-16 2021-08-31 Bayer Healthcare Llc Red blood cell targeted factor VIII and method of using the same
BR102017005783A2 (pt) 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
TW202506732A (zh) 2018-05-07 2025-02-16 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
EP3861127A1 (en) * 2018-10-04 2021-08-11 Thrombosis and Coagulation AB Method for the determination of protein s levels
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
CN114686444B (zh) * 2020-12-31 2024-05-31 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用
CN114686443B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US4912207A (en) 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
WO1990010081A1 (en) * 1989-02-17 1990-09-07 Codon Soluble analogs of thrombomodulin
US6063763A (en) 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5466668A (en) 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
US5256770A (en) 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
KR930008093B1 (ko) 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
JPH0578397A (ja) * 1991-01-29 1993-03-30 Sumitomo Pharmaceut Co Ltd 血栓溶解タンパク質
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
DK1069185T3 (da) * 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
WO2001070984A2 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US6632791B1 (en) 2000-06-21 2003-10-14 Schering Aktiengesellschaft Thrombomodulin analogs for pharmaceutical use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AU2003201159A1 (en) 2002-01-08 2003-07-24 Bayer Healthcare Ag Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
HK1080372A1 (zh) 2002-05-01 2006-04-28 Schering Aktiengesellschaft 作为抗凝剂的新型组织因子目标抗体
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants

Similar Documents

Publication Publication Date Title
JP2005532045A5 (https=)
RU2004135306A (ru) Новые антитела к тканевому фактору в качестве антикоагулянтов
JP2005538046A5 (https=)
Bochenek et al. Role of endothelial cells in acute and chronic thrombosis
Bíró et al. Studies on the interactions between C‐reactive protein and complement proteins
Hellwage et al. Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin
Waters et al. Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein
JP2004523205A5 (https=)
Idell et al. Fibrin turnover in lung inflammation and neoplasia
JPH06502307A (ja) 血液凝固タンパク質のアンタゴニストおよびその利用方法
DK1446157T3 (da) Antistoffer til inhibering af blodkoagulation og fremgangsmåder til anvendelse deraf
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
JP2006512894A5 (https=)
Muzykantov et al. Immunotargeting of erythrocytes-bound streptokinase provides local lysis of a fibrin clot
JP2001095563A5 (https=)
Dyr et al. Molecular arrangement of adsorbed fibrinogen molecules characterized by specific monoclonal antibodies and a surface plasmon resonance sensor
EP0668875A1 (en) Clot directed anticoagulant, process for making same and methods of use
Kawecki et al. Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation
Develter et al. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody
Laich et al. Complement C4bC2 complex formation: an investigation by surface plasmon resonance
CN105517565A (zh) 组织纤溶酶原激活物抗体及其用途
WO2001064876A3 (en) Human schizophrenia gene
CN114981661B (zh) 用于诊断与嗜中性粒细胞胞外陷阱相关的纤溶功能不全的方法
JP2003128577A (ja) 血管増殖性疾患の予防および治療のための血液凝固ｖｉｉ因子活性化プロテアーゼの使用
JPH07138296A (ja) Ｃｓｖｔｃｇ特異的腫瘍細胞の接着受容体の精製及び特性付け